PCM
SLS icon

Prelude Capital Management’s SELLAS Life Sciences SLS Stock Holding History

Prelude Capital Management’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-58,338
Closed -$72.9K – 1559
2024
Q3 		$72.9K Buy
58,338
+2,612
+5% +$3.19K 0.01% 1186
2024
Q2 		$66.3K Buy
+55,726
New +$75.8K 0.01% 1134
2022
Q2 		– Sell
-31,125
Closed -$208K – 2113
2022
Q1 		$208K Buy
+31,125
New +$182K 0.01% 1250
2017
Q3 		– Hold
0
– – – 1927
2017
Q2 		– Sell
-5
Closed -$4.35K – 1857
2017
Q1 		$5K Buy
+5
New +$8.28K ﹤0.01% 1411

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.57B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return